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Abstract
The host vasculature is believed to constitute the principal route of dissemination of Neisseria meningitidis (Nm) throughout
the body, resulting in septicaemia and meningitis in susceptible humans. In vitro, the Nm outer membrane protein Opc can
enhance cellular entry and exit, utilising serum factors to anchor to endothelial integrins; but the mechanisms of binding to
serum factors are poorly characterised. This study demonstrates that Nm Opc expressed in acapsulate as well as capsulate
bacteria can increase human brain endothelial cell line (HBMEC) adhesion and entry by first binding to serum vitronectin
and, to a lesser extent, fibronectin. This study also demonstrates that Opc binds preferentially to the activated form of
human vitronectin, but not to native vitronectin unless the latter is treated to relax its closed conformation. The direct
binding of vitronectin occurs at its Connecting Region (CR) requiring sulphated tyrosines Y56 and Y59. Accordingly, Opc/
vitronectin interaction could be inhibited with a conformation-dependent monoclonal antibody 8E6 that targets the
sulphotyrosines, and with synthetic sulphated (but not phosphorylated or unmodified) peptides spanning the vitronectin
residues 43–68. Most importantly, the 26-mer sulphated peptide bearing the cell-binding domain 45RGD47 was sufficient for
efficient meningococcal invasion of HBMECs. To our knowledge, this is the first study describing the binding of a bacterial
adhesin to sulphated tyrosines of the host receptor. Our data also show that a single region of Opc is likely to interact with
the sulphated regions of both vitronectin and of heparin. As such, in the absence of heparin, Opc-expressing Nm interact
directly at the CR but when precoated with heparin, they bind via heparin to the heparin-binding domain of the activated
vitronectin, although with a lower affinity than at the CR. Such redundancy suggests the importance of Opc/vitronectin
interaction in meningococcal pathogenesis and may enable the bacterium to harness the benefits of the physiological
processes in which the host effector molecule participates.
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Introduction
Mucosal bacteria possess complex mechanisms of targeting their
host cellular adhesion molecules and, in many cases, they adhere to
specific host receptors or soluble effectors and consequently acquire
enhanced colonisation and virulence potential. Understanding the
molecular nature of such interactions may help identify possible
targets of future strategies for prevention of infection or for altering
the course of pathogenesis. In this study, we have analysed in detail,
the molecular mechanisms by which Neisseria meningitidis (Nm,
meningococcus), a human pathogen, interacts with serum vitro-
nectin(Vn), whichcontains an RGD tripeptidesequence recognised
by cellular integrins such as avb3 and avb5. As these may be
expressed by endothelial cells throughout the body, this interaction
has the potential to enable Nm to attach to various human vascular
barriers, as has been demonstrated in vitro [1,2].
Such Nm-endothelial interactions are particularly significant
during the course of meningococcal pathogenesis; as, although Nm
is a common mucosal coloniser (up to 30% of healthy human
population may carry the organism), it is capable of causing
disseminated infections in which the host vasculature provides the
primary means of distribution to distal tissues. The process of
breaching the vascular endothelial barrier may involve cellular
entry, and invasion of endothelial cells of distinct origins as has
been observed in a number of in vitro studies [2,3,4,5]. It has been
shown that meningococcal Opc protein, a major outer membrane
adhesin, carries the property of cellular invasion, especially for
endothelial cells [1,2,3,4].
Meningococci are capsulate bacteria and the functional efficacy
of their subcapsular integral outer membrane adhesins such as
Opc (and Opa, a related but distinct class of opacity proteins)
increases when bacteria become acapsulate or in situations when
their cognate target cell surface receptor expression is enhanced.
This occurs following conditions in the host that increase the
circulation of inflammatory cytokines. Increased receptor density
serves to overcome the inhibitory effects of bacterial surface
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lated cells have also shown that both acapsulate and capsulate
phenotypes of Nm may invade human cells in an Opc- or Opa-
dependent manner [1,2,4,6]. It appears that in the case of
capsulate phenotypes, additional adhesins such as pili (fimbriae)
that traverse the capsule greatly increase the efficiency of initial
binding to target cells; this may then lead to secondary more
efficient interactions via the subcapsular bacterial adhesins [4,6,9].
Opc-mediated interactions have also been shown to result in a
level of bacterial transcytosis across the endothelial barriers in vitro
[3,10]. Although not universally present in Nm, Opc is expressed
in numerous clinical isolates of Nm and retained by several
meningococcal hypervirulent clonal lineages. Notably, it has been
suggested that Opc expression may influence Nm pathogenic
process thus altering the clinical profile of meningococcal disease.
For example, Nm strains of the ET-37/ST11 clonal complex that
lack the opc gene [11,12] have been reported to cause serious cases
of septicaemia [13,14] but have a relatively low tendency to cause
meningitis. This has led to the notion that Opc expression may
enhance the bacterial ability to cause meningitis; perhaps
suggesting an important role of the Opc protein in breaching
the endothelial barrier to enter the brain [4]. This notion was
further supported by the latter study that used Opc-deficient and
Opc-expressing isolates of meningococcal clonal complexes ET-
37/ST11 and ET-5/ST32 respectively [15]; the former were not
able to cross human brain microvascular cell (HBMEC)
monolayers in vitro [4]. Opc-deficient bacteria in our earlier
studies also did not invade human umbilical vein endothelial cells
(HUVECs) [2,3].
Opc is a transmembrane protein of the beta barrel family with
five surface-exposed loops. The protein is basic in nature and has a
prominent surface loop 2. Together, the surface loops of Opc may
form a positively charged crevice that may accommodate
negatively-charged molecules [16,17,18]. More recent studies
suggest that an induced fit mechanism, involving conformational
changes in Opc, may operate for the recognition of molecular
targets by the adhesin [19]. Opc has been shown to bind to heparin-
like molecules and to heparan sulphate proteoglycans (HSPG) on
human epithelial cells in vitro [20]. Its mechanisms of targeting
endothelial cells are distinct and Nm requires serum factors to bind
to HUVECs [1,2]. In these studies, the main serum factor involved
was identified as vitronectin; fibronectin (Fn) also bound directly to
Opc
+ Nm, but to a lesser extent than Vn. This resulted in the
localisation of the bacteria to endothelial RGD-recognising
integrins particularly avb3 [1]. In contrast, the studies of Unkmeir
et al. [4] demonstrated a prominent role of Fn but not Vn in Nm
interactions with HBMECs. One notable observation made during
our studies on HUVECs was that when using purified Vn, certain
but not all preparations of Vn supported bacterial adhesion. As Vn
may occur in a number of conformational forms [21,22,23], we
hypothesised that Opc may only bind efficiently to certain
conformational forms of Vn. In this regard, Vn is believed to
undergo ligand-induced conformational change to exert its role in
key processes of coagulation, fibrinolysis and in the protection of
bystander cells against the terminal complement membrane attack
complex (MAC) [23]; the processes of particular importance during
Gram negative bacterial sepsis [24,25]. Normally, Vn exists in its
closed native conformation (depicted in summary final figure)
[23,26,27] which has been shown to undergo conformational
change on its activation by some of its physiological ligands which
include, thrombin-antithrombin complex (TAT) and MAC. In one
study, these were shown to be elevated during meningococcal sepsis
[28]. Vitronectin conformational activation reveals a number of
cryptic epitopes including the full exposure of the heparin binding
site at the Vn C-terminal domain and the tyrosine sulphated
residues in the connecting region (CR) of Vn (Y-S, final figure).
Notably,twotyrosinesinthisregionhavebeenshownunequivocally
to be sulphated in secreted vitronectin [29,30,31]. The active or
unfolded Vn conformation could also be more favourable for
cellular targeting via the cell binding domain (RGD) [27,32]. In
quantitative terms, Vn in fresh plasma is present at ,300 mg/ml in
its native conformation. However, ,2% may be in its conforma-
tionally active form. This activated Vn concentration increases
during blood coagulation to ,7% [22,23,33].
The principal aim of our study described here was to assess the
molecular mechanisms of Opc interactions with Vn and to
examine the potential roles of Vn and Fn in Nm adhesion and
invasion of human endothelial cells. Our studies have shown that
Nm Opc can interact with Vn directly but its efficient interactions
can only be shown with activated Vn. We have also demonstrated
a novel mechanism of bacterial adhesion to human Vn. This
involves direct binding to the Vn tyrosine sulphated region in
which the sulphate moieties are necessary for bacterial adhesion.
This mechanism may also be used in binding to vitronectin from
other sources (bovine, murine). We further present studies
comparing direct and indirect binding of Opc
+ Nm to activated
Vn, the latter occurs via heparin. By uncovering the underlying
mechanisms of Opc/Vn interactions, this study additionally
provides robust evidence and a rationale for the previous
apparently divergent reports regarding the roles of serum proteins,
especially Vn, in supporting meningococcal interactions with
human endothelial integrins and subsequent cellular invasion.
The studies on Vn in relation to Nm seem pertinent also; as
notably, meningococcal dissemination is associated with activation
of coagulation, fibrinolysis and complement systems; the processes
in which vitronectin is intimately involved as a scavenging factor
for their end-products [24,25,28]. Accordingly, during meningo-
coccal sepsis, consumption of plasma Vn has been shown to occur
due to its widespread activation and subsequent removal from the
circulation [28]. This would suggest that during intravascular
spread, meningococci are likely to encounter a continuous supply
of activated Vn in circulation.
Author Summary
Neisseria meningitidis is a human pathogen that can cross
the natural cellular barriers to reach the blood and the
brain, causing septicaemia and meningitis. One of its
surface molecules, Opc, has the capacity to attach to
human cells lining the blood vessels. In vitro, the bacterium
can do this by coating itself with the human serum factor
vitronectin; and, by mimicking as vitronectin, it can bind to
human cellular vitronectin-binding proteins (receptors). In
this study, we have investigated the structural features of
vitronectin that N. meningitidis recognises; such knowl-
edge could help develop future strategies to control
bacterial spread. We describe two different aspects of
bacterial binding to vitronectin and demonstrate that one
of these is a novel method, which occurs directly through
the sulphated tyrosines of vitronectin available only when
the molecule presents itself in an unfolded form. Such
unfolded or activated vitronectin levels may be elevated
during bacterial presence in the blood. Thus our observa-
tions imply that when bacteria appear in the blood, their
presence may help to generate the form of vitronectin that
they require for binding to and invading the cells that line
human blood vessels to spread throughout body tissues
including the brain.
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of serogroup A strain C751, which have been characterised
extensively and used in a number of previous studies on
meningococcal-endothelial interactions in order to unequivocally
define the role of the Opc protein [1,3,10,34]. In addition, to
evaluate the role of vitronectin during infection, we have also used
capsulate isolates of a serogroup B strain MC58 representing a
phenotype that may be isolated from the blood (replete with
capsule, pili, Opa and Opc).
Results
Relative efficacy of vitronectin and fibronectin in binding
to Opc-expressing Nm and supporting adhesion and
invasion of human endothelial cells
Previous studies have assigned different serum proteins as
bridging molecules involved in mediating Nm Opc-dependent
interactions with human endothelial cells of distinct origins: Vn for
human umbilical vein endothelial cells (HUVECs) and Fn (but not
Vn) for human brain microvascular endothelial cells (HBMECs)
[1,2,4].
To clarify the adhesion supporting roles and mechanisms of
Opc targeting of serum components, in the current studies, the
roles of the serum proteins were further examined. Initially, the
ability of Opc
+ and Opc
2 isolates to acquire serum factors from
normal human serum was demonstrated by the exposure of Opc
+
and Opc
2 variants of strain C751 to normal human serum (NHS),
followed by western blotting of adsorbed bacteria. Using anti-Vn
and anti-Fn antibodies to overlay the blots, direct binding of Opc
+
Nm to both these serum proteins could be seen; little or no binding
was observed with Opc-deficient bacteria (Figure 1A).
In further experiments, the relative abilities of acapsulate Nm
strain C751 and capsulate MC58 to attach to and invade
HBMECs in the presence of NHS were compared. Several
features were apparent from these studies. In serum supplemented
medium, the strain C751 isolate (acapsulate and lacking pili and
Opa adhesins) required Opc for cellular adhesion and invasion
(Figures 1B and C). Whereas, capsulate MC58 (with pili and Opa
expression), did not require Opc for a significant level of cellular
adhesion. However, the Opc-deficient isolate of MC58 was not
significantly invasive. In this strain however, Opc expression
conferred both increased adhesion and invasion properties to the
capsulate bacteria (Figures 1B and 1C). Cytochalasin D controls
were used to confirm cellular invasion as assessed by gentamicin
protection assays [35] (Figure 1C).
To assess the efficacy of different serum factors in supporting
cellular adhesion and invasion of the above phenotypes, purified
serum factors were used to supplement the infection media. We
compared the native, folded Vn (nVn) as well as conformationally
altered activated Vn (aVn) in addition to cellular and plasma forms
of Fn (cFn, pFn). Of the purified proteins, the most efficient
interaction was observed with aVn followed by pFn and then cFn.
No significant cellular interactions were observed with nVn or
unsupplemented media (Figure 1D shows the full analysis for Opc-
expressing C751 isolate). For the capsulate piliated MC58, similar
overall results were obtained. In Figure 1E, adhesion and invasion
levels with the most effective serum components are shown for
MC58. As in Figure 1B, a basal level of adhesion was observed for
MC58 derivative even in the absence of Opc expression and was
largely unaffected by the media supplements; but notably, no
significant invasion was seen. The basal level of adhesion of the
Opc
+ isolate in the unsupplemented medium and that of Opc
2
isolate under all the conditions tested is largely due to the pilus
expression (see discussion). From these studies it is noteworthy that
in a physiologically relevant meningococcal phenotype (MC58
phenotype used here), the subcapsular adhesin Opc plays an
important role in endothelial cell invasion; it also enhances cellular
adhesion. Both these functions appear to be largely dependent on
the activated form of serum vitronectin.
Preferential interactions of Opc
+ N. meningitidis with
activated vitronectin
(a) Activated Vn is depleted from serum on sequential
incubation with Opc
+ Nm. To assess the relative preference of
Opc
+ Nm for aVn, nVn and Fn when present simultaneously in
normal human serum, a serum sample was incubated sequentially
with three fresh suspensions of acapsulate Opc
+ C751 isolate.
Aliquots of the serum after each extraction were analysed for
remaining levels of the proteins by immuno-dot blotting
(Figure 2A). Total Fn and total Vn levels were determined by
the use of polyclonal antibodies. As activated/unfolded human Vn
has been shown to reveal cryptic epitopes, one of which is
recognised by the monoclonal antibody (mAb) 8E6, this
conformation-dependent antibody was used specifically to detect
aVn in serum [22,36]. The results illustrated that the levels of
activated Vn decreased in NHS dramatically by over 75% with
two sequential Opc
+ bacterial incubations but a relatively small
overall depletion of total Vn or Fn levels (25 and 20% respectively)
occurred even after three extractions (Figure 2A). Less than 10%
of 8E6-binding component was lost from serum with Opc-
deficient bacteria (Figure 2A).
In assessing the level of decrease of the serum proteins, it is
pertinent to note that activated Vn in whole serum may amount to
over 7% [33]. However, in decomplemented serum, which is
subjected to heat treatment, additional conversion of nVn to aVn
will occur [22,37]. In two separate experiments, we observed the
level of aVn in serum to increase by 2-3-fold after heat treatment
as determined by 8E6 binding, thus approaching the levels of total
Vn lost (20–25%) after Opc
+ bacterial incubation (Figure 2A).
In complementary experiments, removal of heparin-binding
components from human serum, which removed activated Vn but
not native Vn, almost totally abrogated serum-dependent Nm
interactions (not shown).
To assess capsulate bacterial interactions with serum vitronec-
tin, freshly prepared viable suspensions of Opc
+ and Opc
2
derivatives of MC58 were incubated with NHS. Opc
+ phenotype
was again effective in removing activated Vn which was depleted
by 81% after 3 adsorption cycles (Figure 2B, left). Very little 8E6-
binding component was lost from serum with Opc-deficient MC58
(not shown). In agreement with these observations, when the
adsorbed bacterial pellets were examined for bound Vn using a
polyclonal Vn antibody in a immuno-dot blot assay, the antibody
only reacted with Opc
+ but not Opc
2 MC58 that had been
exposed to NHS (Figure 2B, right).
Overall, the following conclusions can be drawn from the data
presented on the examined serum proteins extracted by Opc
+ and
Opc
2 Nm (Figure 1A and 2): a) that Vn as well as Fn from human
serum bind to Opc
+ Nm (Figure 1A); b) the binding of serum Vn is
facilitated by the expression of Opc (immunoblots in Figures 1 and
2); c) after three sequential extractions with Opc
+ Nm, the
decrease in total Vn levels roughly equal the levels of aVn present
in the decomplemented NHS used. These observations are
consistent with the notion that aVn is extracted in preference to
nVn. This preference for aVn was further investigated in direct
binding assays.
(b) Denaturation of native Vn by heat treatment increases
its recognition by Opc-expressing Nm. To establish further
the importance of Vn conformation, purified preparations of
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interactions in a quantitative ELISA. As adsorption to plastic has
been shown to denature native Vn to variable extents [21,38], the
studies were carried out using bacteria in solid phase and Vn
preparations in fluid phase. Compared to aVn, nVn bound poorly
to Opc
+ bacteria; Opc
2 variant of the same strain did not bind
well to either preparation (Figure 3A). As noted above, mild heat
treatment of nVn has been shown to unfold the protein and
increase its access to the mAb 8E6 [36,37]. When nVn was
subjected to such heat treatment, mAb 8E6 binding increased
(Figure 3B, lower panel) and concurrently Opc
+ (but not Opc
2)
meningococcal interactions increased substantially (Figure 3A).
The data confirm that 8E6 binding and bacterial interactions both
require similar Vn conformations. In addition, when nVn, heated-
nVn and aVn were examined for their adhesion supporting
activities, the heated-nVn behaved in a similar manner to aVn,
Figure 1. Invasion of HBMECs by capsulate and acapsulate meningococci is dependent on Opc-expression and serum components.
(A) To determine the relative binding of the serum proteins to Opc
+ and Opc
2 N. meningitidis, bacteria were incubated with 10% normal human
serum (NHS). The binding of vitronectin (Vn) and fibronectin (Fn) was assessed by applying lysates of serum coated, washed bacteria to SDS-
polyacrylamide gels and western blotting. Anti-Vn and anti-Fn antibodies followed by AP-conjugated secondary antibodies were used to detect the
proteins. Opc-expressing Nm bound to Vn and Fn, whereas Opc-deficient bacteria bound considerably weakly to the proteins. Lane marked NHS was
loaded with the serum sample. The two vitronectin bands shown in the left blot correspond to the two molecular forms of vitronectin (75 and
65 kDa) found in human blood, the lower molecular form results from endogenous cleavage of a small region at the C-terminal end of some Vn
molecules (see reference 26). (B, C) Relative efficiencies of Opc
+ and Opc
2 Nm isolates of strain C751 and MC58 (without or with capsule, pili and Opa
expression respectively) in mediating HBMEC adhesion and invasion in serum supplemented media were determined by viable count and gentamicin
protection assays. To confirm that gentamicin-resistant bacteria were truly internalised, cytochalasin D (CD) was used in some tests to prevent
bacterial uptake into cells. In this case, no bacteria survived the gentamicin treatment (invasion levels indicated by blank columns in C) [35]. (D, E)I n
similar experiments, various purified serum components were compared with NHS in their ability to support HBMEC adhesion and invasion by
acapsulate and capsulate meningococci. When supplemented, the infection media contained 10% NHS or 10 mg/ml of one of the following serum
proteins: activated Vn (aVn), native Vn (nVn), cellular Fn (cFn) and plasma Fn (pFn), as in preliminary experiments, these were found to be the
optimum concentrations required. The most effective serum component was found to be aVn in enhancing both cellular adhesion as well as invasion.
Plasma Fn also supported adhesion and invasion but to a significantly lesser extent (D and E).
doi:10.1371/journal.ppat.1000911.g001
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+ Nm binding to HBMECs
whereas nVn was ineffective (Figure 3C).
Taken together, the above data strongly support the notion that
activated Vn is the preferred form of Vn for Opc interactions. In
further studies described below, we sought to define the molecular
basis of the direct interactions of Opc with human serum Vn.
Opc interactions with aVn are inhibited by the
conformation-dependent mAb 8E6
To identify the binding site of Opc on activated Vn, initially we
investigated if the mAb 8E6 could inhibit Opc-expressing Nm
binding to the activated Vn by immuno-dot blot assays.
Surprisingly, the antibody almost totally inhibited Opc
+ Nm
binding to aVn (Figure 4A) and prevented aVn adsorption from
NHS on to Opc
+ capsulate meningococcal surface (Figure 4B).
Very low levels of Vn adsorbed on to some Opc
2 cultures could be
due to Opc
+ phase variants that naturally arise or due to non-
specific adsorption of Vn on bacterial surface; although, the data
do not rule out the possibility of Vn binding to other bacterial
Figure 2. Activated vitronectin is adsorbed preferentially from
serum by capsulate and acapsulate Opc-expressing N. meningi-
tidis. (A) To assess which serum protein is preferentially removed from
serum by Opc
+ Nm, a sample of normal human serum was adsorbed
three times sequentially with Opc-expressing phenotype of acapsulate
C751. At each stage, aliquots of the adsorbed serum samples were
retained. Unadsorbed serum and adsorbed samples were analysed by
immuno-dot blot assay (followed by densitometric analysis) for
activated and total Vn/Fn levels using the mAb 8E6 and the polyclonal
rabbit anti-Vn or anti-fibronectin antibodies. The levels of each of these
components extracted from serum by Opc
+ Nm as a percent of the total
present at the start of extraction are shown. In control experiments, in
which Opc
2 Nm were used, 8E6 binding to 3 x adsorbed serum did not
alter significantly and amounted to less than 10% loss of aVn (blank
column). (B) In a similar experiment, a sample of NHS was adsorbed




+ bacteria effectively removed a large portion of aVn as assessed by
mAb 8E6 binding to serum samples before and after incubation with
Nm (B, left). Specific removal of Vn from NHS by Opc
+ but not Opc
2
MC58 isolates is apparent from the analysis of serum-adsorbed bacterial
pellets which show that bound Vn was only significantly detectable on
Opc
+ bacteria that were exposed to NHS (B, right).
doi:10.1371/journal.ppat.1000911.g002
Figure 3. Deliberate modification of nVn conformation
increases Opc–expressing meningococcal interactions with
Vn and with HBMECs. (A) Purified native Vn (nVn) was subjected
to limited heat denaturation to relax its folded conformation and reveal
the mAb 8E6 binding site. To assess the levels of binding of Opc
+ Nm to
nVn, heated nVn (h-nVn) and the serum-derived heparin-purified
activated Vn preparation (mAb 8E6 binding form), these proteins were
overlaid on to immobilised Opc
+ and Opc
2 isolates of strain C751 and
Vn binding determined using polyclonal anti-Vn antibody. As bacteria
lacking Opc exhibited the same level of binding to all vitronectin
preparations, these are labelled as (Opc
2/Vn broken lines). (B) The
vitronectin samples used for ELISA were also analysed for their
activation status using the mAb 8E6 and the polyclonal anti-Vn
antibody (r-anti-Vn) by immuno-dot blotting. The conformation-
dependent mAb 8E6 only reacted with aVn and heated nVn
demonstrating the exposure of its epitope on heat treatment of nVn.
Rabbit antibodies also bound more effectively to the same two forms of
Vn suggesting that aVn and h-nVn present larger numbers of epitopes.
(C) Immunofluorescence analysis was performed using confluent
HBMECs infected with Opc
+ and Opc
2 C751 isolates in media
supplemented with aVn, nVn and heated nVn illustrating their relative
abilities in supporting bacterial adhesion. Bacteria were labelled using
anti-Nm antiserum and rhodamine-conjugated secondary antibody.
doi:10.1371/journal.ppat.1000911.g003
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+
and Opc
2 bacteria is substantial, and clearly significant. In
addition, 8E6 significantly inhibited serum-mediated Opc
+ Nm
adhesion and invasion of HBMECs (Figure 4C and 4D). Several
conclusions can be drawn from these observations: that Nm can
bind to activated Vn at a site overlapping or closely positioned to
the mAb 8E6 binding site, that activated Vn recognised by 8E6
may represent a significant portion of the serum component
involved in mediating Nm interactions with HBMECs (Figure 4D)
and that other serum components may also participate in
supporting bacterial binding to human endothelial cells but to a
relatively lesser extent than activated Vn.
Identification of the vitronectin region involved in
binding to N. meningitidis Opc
Relatively mild acid hydrolysis of Vn using conditions that
destroy the labile O-linked sulphate groups has been reported to
diminish the binding of the mAb 8E6 [30]. This mAb has been
shown to require sulphation of the tyrosine residues (Y56 and Y59)
of the connecting region of Vn for binding [30,31]. Accordingly,
Vn expressed in E. coli does not bind to 8E6 [22]. To assess if
bacterial binding is also affected by such acid treatment of Vn,
aVn samples treated at 80uC with 1 M HCl for increasing time
periods (as described in methods) were dotted on to nitrocellulose
and overlaid with either 8E6, polyclonal anti-Vn antibody or Opc
+
Nm. The polyclonal antibody was used to assess if the overall
vitronectin structure is affected by the acid treatment. The mAb
8E6 binding and Opc-expressing bacterial interactions (both
acapsulate C751 and capsulate MC58) with Vn declined in
concert, and no binding of either could be detected when Vn was
treated for .15 min (Figures 5A and 5B). In contrast to 8E6,
polyclonal anti-Vn antibody still bound to Vn significantly at the
end of acid hydrolysis (Figure 5A).
Overall, these data suggest that the binding sites of the mAb
8E6 and Nm Opc share similar characteristics and may be related
to the sulphation of tyrosines at sites 56 and 59. However, it could
be argued that acid hydrolysis may also destroy other specific
epitopes not detected by the polyclonal antibody. Therefore, to
further assess if tyrosine sulphation is required for bacterial
binding, we used sulphated and unsulphated peptides spanning the
Vn region 48–68 (Figure 5C), termed VA-21S and VA-21
respectively. These peptides otherwise carried no further modifi-
cations. As the mAb 8E6 binding requires sulphated tyrosines,
only VA-21S would be expected to bind to the antibody and
Figure 4. Monoclonal antibody 8E6 against a cryptic epitope of vitronectin inhibits Opc-mediated interactions of N. meningitidis. (A)
The ability of anti-Vn antibodies 8E6 and VIT-2 to inhibit bacterial binding to immobilised aVn was investigated by immuno-dot blot assays in the
presence or absence of the anti-Vn antibodies added at 10 mg/ml prior to Opc
+ acapsulate Nm additions. Relative levels of Opc
+ Nm binding is shown
as arbitrary units determined by densitometric analysis as described in the text. 8E6 but not VIT-2 inhibited direct bacterial binding to purified aVn. (B)
8E6 also prevented adsorption of aVn on to capsulate Opc
+ bacteria from NHS; the procedure was carried out as described in the legend to figure 2.
The mAb 8E6 when present was used at 10 mg/ml. (C, D) The effect of 8E6 on adhesion/invasion of HBMEC by acapsulate Opc
+ bacteria in the
presence of 10% NHS was assessed using immunofluorescence adhesion assay (C) or viable count assays (D) performed as described in methods.
Bacteria in (C) were labelled using anti-Nm antiserum and rhodamine-conjugated secondary antibody. For controls, either an unrelated primary
antibody (control 1) or secondary antibody only (control 2) were used. As addition of 8E6 results in a significant and a dose-dependent inhibition of
adhesion and invasion (D), activated Vn appears to be one of the main serum factors supporting Nm interactions with human endothelial cells.
doi:10.1371/journal.ppat.1000911.g004
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binding of the mAb 8E6 to the whole immobilised aVn sample was
prevented in the presence of added competing VA-21S but not
with VA-21 (Figure 5D). Similarly, Opc
+ Nm binding to aVn was
also specifically and significantly inhibited by VA-21S peptide in a
concentration dependent manner but not by VA-21 (Figure 5E).
Figure 5. The nature of the vitronectin epitope recognised by N. meningitidis Opc. (A, B) Acid hydrolysis of vitronectin. Immuno-dot
blot assays were performed using acid-treated (1 M HCl, 80uC), immobilised aVn on to nitrocellulose strips. The strips were blocked and overlaid with
antibodies or bacteria and analysed for the ability of Vn to retain binding of the mAb 8E6 and polyclonal rabbit anti-Vn antiserum (A) or acapsulate
(C751) and capsulate (MC58) Opc
+ Nm (B). Binding of bacteria and 8E6 declined simultaneously during acid hydrolysis of Vn known to hydrolyse the
sulphate groups. (C–E) Studies using synthetic vitronectin peptides. (C) Sequence of synthetic peptides corresponding to the residues 48–68
containing the 8E6 binding site of vitronectin. The peptide VA-21 was synthesised in a non-sulphated form whereas the peptide named VA-21S was
sulphated at residues 56 and 59 as in vitronectin. (D) In a competition immuno-dot blot assay, the ability of the mAb 8E6 to bind to immobilised aVn
in the absence or presence of the peptides was assessed. 8E6 binding was quantified using AP-conjugated rabbit anti-mouse secondary antibody
followed by densitometry. VA-21S but not VA-21 inhibited 8E6 binding to immobilised aVn. (E) In an ELISA, the binding of acapsulate C751 Opc
+ Nm
overlaid on to immobilised aVn was inhibited significantly by the addition of increasing concentration of synthetic peptide VA-21S but to a very low
extent with the equivalent unsulphated peptide VA-21. (F) To assess the efficacy of VA-21 and VA-21S to inhibit aVn-mediated adhesion and invasion
by acapsulate and capsulate Opc
+ Nm, viable count experiments were performed. VA-21 or VA-21S peptides (25 mg/ml) were used to pre-coat
meningococci (15 min. incubation) which were then added to HBMEC monolayers in infection medium supplemented with aVn (10 mg/ml). VA-21
had no significant effect on adhesion (blank columns) or invasion (filled columns). In contrast, VA-21S reduced cellular adhesion and invasion
significantly with a more dramatic effect on invasion levels of both strains.
doi:10.1371/journal.ppat.1000911.g005
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an epitope within the CR residues 48–68 and require sulphation of
tyrosines for effective interactions. The two peptides were also
assessed in their ability to inhibit aVn-dependent bacterial binding
and invasion of HBMECs. VA-21S, but not VA-21, inhibited
Opc
+ Nm adhesion to the endothelial cells, it also dramatically
inhibited invasion of HBMECs by both capsulate and acapsulate
Nm (Figure 5F).
Demonstration of the direct binding of Opc
+ N.
meningitidis to sulphated but not phosphorylated
vitronectin peptides spanning the residues 43–68
As the 21-mer peptides (VA-21/S) used above proved to be
resistant to immobilisation on a variety of solid surfaces, further
experiments were carried out on biotin-tagged 26-mer peptides
spanning the Vn region 43-68 (Figure 6A). It is noteworthy that
these peptides do not contain any of the heparin binding domains
of Vn (see final figure). In addition to the unmodified peptide (VA-
26), both sulphated (VA-26S with Tyr56S, Tyr59S) as well as
phosphorylated (VA-26P with Thr50P, Thr57P) were derived. The
latter peptide design was chosen as protein kinase CK2 (casein
kinase 2) has been reported to phosphorylate T50 and T57 of Vn
extracellularly [39,40,41].
Initially, we compared the effects of the three peptides in a
competitive ELISA to assess their ability to inhibit Opc
+ Nm
binding to immobilised aVn. In addition, we also subjected the
peptides to mild acid-hydrolysis to remove the sulphate residues
from VA-26S. Such a treatment (,20 minutes in 1 M HCl at
80uC) was not expected to affect the phosphorylation of the VA-
26P peptide as prolonged hydrolysis .1.5 h in 6 M HCl at 110uC
in vacuum has been shown to be required to extract intact
phosphothreonines and phosphoserines from proteins [42,43].
Accordingly, mAb 8E6 binding was abrogated but the phosphate
residues on VA-26P were not at all affected by acid-treatment and
the anti-phosphothreonine antibody binding remained unchanged
(Figures 6B and S1). Concurrently, only the untreated VA-26S
inhibited Opc
+ Nm binding to aVn (Figure 6B). The data suggest
that the VA-26S peptide behaved identically to the slightly shorter
untagged peptide (Figure 5E) and that neither the phosphorylated
nor the unmodified peptide could interfere with bacterial binding
to aVn.
To assess if bacteria could bind directly to peptides, ELISA
plates with immobilised extravidin were loaded with increasing
concentrations of the biotinylated peptides. The peptide binding
was demonstrated by using 8E6 and anti-Thr-P antibodies (Figure
S2A). Binding of the unmodified peptide (VA-26) was determined
by indirect ELISA in which extravidin plates were sequentially
exposed to the biotinylated peptides VA-26 followed by VA-26S.
The binding of VA-26S was then assessed by the use of mAb 8E6
(Figure S2B). When bacterial binding was examined to peptide-
loaded plates, the level of Opc
+ bacterial binding paralleled the
VA-26S peptide-loading, reaching a saturation point at about
1 mg/ml peptide concentration used for immobilisation (Figures 6C
and S2A). In addition, Opc
+ bacterial adhesion was observed only
when the plates contained VA-26S but not with VA-26 or VA-26P
peptides (Figure 6D).
The above data provide compelling evidence that sulphated
tyrosines of vitronectin create a binding epitope for Opc and show
that negatively charged phosphorylated threonine residues do not
substitute for sulphated tyrosine residues in Opc-mediated binding
at the CR of Vn. Whether phosphate groups, when present in
addition to sulphate groups, further strengthen the interactions of
the synthetic peptides was not investigated.
The sulphated peptide spanning the Vn residues 43–68
(VA-26S) contains features required for cellular adhesion
and invasion
The VA-26 peptides with an RGD sequence upstream of the
tyrosine sulphation site, as in the native Vn, were used to examine
further the role of the Vn CR in Opc
+ Nm targeting of endothelial
integrins. Using these peptides, specific and significant binding of
Opc
+ bacteria to HBMECs in the presence of VA-26S but not the
other peptides could be demonstrated (Figure 6E). In quantitative
adhesion and invasion experiments, adhesion to and invasion of
HBMECs by both capsulate and acapsulate meningococci was
enhanced by VA-26S in a RGD and tyrosine-sulphation-
dependent manner (Figure 6F and G); as both VA-26 peptide
with an RGD sequence as well as RGDS peptides incubated with
HBMECs prior to the addition of VA-26S precoated bacteria
inhibited bacterial interactions. These studies highlight the
sufficiency of sulphation of the tyrosines and an RGD sequence
as presented in VA-26S for meningococcal invasion of human
brain endothelial cells.
In complementary experiments, we also investigated the effect
of VA-21 and VA-21S to inhibit VA-26S-mediated HBMEC
interactions. In accordance with its effect on aVn-mediated
cellular interactions (Figure 5F), dramatic inhibition of VA-26S-
mediated adhesion and invasion occurred with VA-21S; VA-21
had no effect. With VA-21S, the inhibition of adhesion of C751
Opc
+ Nm approached 80% and invasion 100%. For piliated
capsulate Opc
+ MC58, adhesion was inhibited less well (,40%, as
pili continue to assist in cellular adhesion) but invasion was
inhibited by over 80% (data not illustrated).
Species specificity of Opc and 8E6, and their
requirements for binding to vitronectins
As bovine serum is frequently used as a supplement in growth
and infection media and mice are sometimes used for studies on
systemic meningococcal infections, vitronectins of these animal
origins relevant to Nm studies were examined for conservation of
the 8E6/Nm binding sites. The relevant sequences of the human,
bovine and murine vitronectins are shown in Figure 7A. Tyrosine
at position 56 is conserved in all three vitronectins, and Y59 is
present in human and murine but not bovine Vn. There are also
significant differences in bovine and murine vitronectins especially
in residues down-stream of Y56. Notably also, there is a tyrosine
residue at position 61 in both bovine and murine Vn not present in
human Vn. Bovine Vn also does not contain threonine residues at
positions 50 and 57. Initially, the reactivity of the mAb 8E6 with
immobilised vitronectins (all prepared using heparin-sepharose)
from distinct sources was analysed by ELISA. Only human Vn
was recognised by 8E6 (Figure 7B). In a previous study, efficient
recognition of Vn peptides by 8E6 was shown to be dependent on
sulphated Y59, although the maximum 8E6 binding occurred
when both Y56 and Y59 were sulphated [30]. The three Vn
samples were also subjected to limited heat treatment to unfold
any closed conformers. This treatment did not alter the mAb 8E6
binding pattern (not shown).
To assess bacterial recognition of the serum proteins, immobi-




+ bacteria bound to human Vn to the greatest
extent but significant levels of binding to bovine and murine Vn
(compared with Opc
2 Nm) also occurred (Figure 7C). In
accordance with 8E6 recognition of human but not other
vitronectins, inclusion of 8E6 with Opc
+ Nm in overlay
experiments resulted in inhibition of bacterial binding to human
Vn observed above (Figure 4A) but not to other vitronectins (data
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vitronectins did not alter the pattern of bacterial binding (not
shown).
Bovine serum enhanced endothelial interactions of Nm has
been reported previously [1]. Further, in accordance with Nm
Opc binding to the animal vitronectins, both bovine and murine
Figure 6. The VA-26S sulphated peptide contains the features required and sufficient for Opc binding and cellular invasion. (A)
Structures of the biotinylated peptides spanning the Vn region 43–68. VA-26 peptide was unmodified other than at the N-terminal residue which was
linked to biotin. Additionally, VA-26S contained sulphated Y56 and Y59 and VA-26P contained phosphorylated T50 and T57. (B) Using 25 mg/ml each of
untreated and prior acid-hydrolysed peptides, their relative abilities to inhibit C751 Opc
+ bacterial interactions with immobilised aVn were examined
by ELISA. Only untreated VA-26S inhibited bacterial binding to aVn. The table summarises the effect of acid-treatment on the peptides (see Figure
S1), only the sulphated residues are hydrolysed and consequently only the mAb 8E6 binding to VA-26S is affected after treatment. (C) To examine the
direct binding of Opc
+ Nm of strain C751 to VA-26S and VA-26, the peptides were first immobilised on extravidin-containing plates (Figure S2).
Bacterial binding was detected using anti-Nm antiserum. Opc
+ Nm bound significantly only to VA-26S. (D) Relative levels of direct binding of Opc
+
and Opc
2 Nm to immobilised VA-26, VA-26S and VA-26P peptides by ELISA. In each case, saturating levels of peptides were used (5 mg/ml each,
Figure S2). Bacterial binding as detected using anti-Nm antiserum shows only VA-26S and Opc
+ Nm interactions. (E) Immunofluorescence analysis of
the ability of VA-26 peptides, which contain the integrin-binding domain RGD, to mediate bacterial binding to HBMECs. Opc
+ bacteria but not Opc
2
bacteria localised on to HBMECs in significantly higher numbers in the presence of VA-26S (and aVn control) but not with other peptides (all used at
20 mg/ml). (F and G) To assess the efficacy of VA-26S in mediating acapsulate and capsulate bacterial adhesion and invasion, viable count
experiments were performed using VA-26 or VA-26S peptide-coated bacteria. In some experiments VA-26 (20 mg/ml) and RGDS (0.25 mM) were used
to preincubate HBMECs to act as inhibitors of RGD-mediated binding of VA-26S-coated bacteria. The data illustrate that two key features (sulphated
tyrosines and RGD) present in VA-26S are required and sufficient for mediating bacterial invasion of HBMECs.
doi:10.1371/journal.ppat.1000911.g006
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HBMECs (Figure 7D).
Similarities of Opc interactions with human, bovine and
murine vitronectins
The mAb B306 against an epitope on the loop 2 of Opc [44]
has been shown previously to inhibit Nm Opc-mediated, Vn-
dependent interactions with human endothelial cells [2,3]. To
assess if the direct binding to the various vitronectins can be
inhibited similarly by this mAb, first an ELISA was performed
using increasing concentrations of the mAb B306 and another
mAb, 154,D-11, that binds to an epitope in loops 4/5 [44] to
inhibit bacterial binding to aVn using immobilised bacteria.
Concentration-dependent inhibition of binding of aVn to Opc
+
Nm was observed in the presence of B306 but not with the mAb
154,D-11 (Figure S3). Similarly, Opc
+ Nm binding to immobilised
bovine and murine Vn was inhibited with B306 whereas 154,D-11
had significantly less inhibitory effect on bacterial binding
(Figure 7E). Taken together, the data indicate that similar
mechanisms may determine the direct binding of Opc to the
three vitronectins.
To investigate if binding to bovine and murine Vn was
dependent also on sulphated tyrosines, the Vn preparations were
subjected to acid hydrolysis prior to the examination of Opc
+ Nm
binding by ELISA. In each case, acid hydrolysis for 20 min
resulted in abrogation of bacterial binding (Figure 7F) consistent
with the role of Y-S in bacterial binding. Further in a competition
ELISA, VA-21S peptide significantly inhibited Opc
+ Nm binding
Figure 7. Species specificity of Opc and 8E6 and their binding requirements. (A) Sequences flanking the fully conserved Y56 in human (Hu),
bovine (Bo) and murine (mouse, Mo) vitronectins aligned using MegAlign Lasergene software (DNASTAR). The variant residues in bovine and murine
vitronectins are underlined. (B) Reactivity of the mAb 8E6 with immobilised vitronectins from distinct sources was analysed by ELISA demonstrating
its specificity for human Vn. (C) In a similar experiment, the binding of C751 Opc
+ and Opc
2 Nm to immobilised vitronectins was assessed by bacterial
overlay. Although human Vn was the most recognised, Opc
+ Nm also bound to bovine and mouse Vn at significantly higher levels compared with
Opc
2 Nm. (D) The relative abilities of bovine and mouse sera (used at 10%) and purified vitronectins (10 mg/ml) to support C751 Opc
+ Nm binding to
HBMECs were assessed by immunofluorescence analysis as described in methods. (E) Two mAbs against Opc known to bind to loop 2 (B306) or loops
4/5 (154,D-11) were used in competition studies to assess their ability to block Opc/Vn interactions. Bacterial suspensions were pre-incubated with
30 mg/ml of the antibodies for 20 min prior to addition to Vn. B306 against loop 2 of Opc caused significantly higher inhibition of meningococcal
binding to all three Vn samples. (F) The potential role/s of sulphated tyrosines in each of the vitronectins was assessed by acid hydrolysis as described
in methods. The relative levels of bacterial binding to the animal vitronectins are shown as blank columns (bovine Vn: middle columns, mouse Vn:
right columns) and to human Vn (used for comparison) as filled columns. Percent binding compared with untreated vitronectins demonstrates similar
decline in bacterial binding to all three proteins concurrently with the decline in 8E6 binding (monitored simultaneously using human Vn shown
below the graph). (G) In a competitive ELISA, VA-21S peptide but not VA-21 inhibited bacterial binding to immobilised bovine and murine
vitronectins in a manner similar to human vitronectin suggesting similar mechanisms of targeting the three vitronectins.
doi:10.1371/journal.ppat.1000911.g007
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overall, the data indicate somewhat variant requirements for Nm
Opc and the mAb 8E6 binding to the human and animal
vitronectins, however, sulphation of tyrosine appears to be
important in each case.
Dual mechanisms of interactions of N. meningitidis Opc
protein with human vitronectin
Besides the sulphated tyrosines, Vn molecule has been shown to
contain several heparin-binding domains (HBD), one of which,
located in the C-terminal region spanning the residues 341–380
has been shown to mediate high affinity interactions with heparin
(see schematic diagram final figure, HBD) [45]. As Opc is also a
heparin-binding protein [20], that Opc may bind to the HBD of
Vn via a heparin bridge is entirely possible; this has been implied
from earlier studies [46]. To investigate the possible and relative
roles of both the CR and the HBD of the activated Vn in Opc
binding, we initially analysed if any heparin or heparin-like
molecules become attached to bacteria grown on solid agar-
containing media as bacterial acquisition of charged molecules
could alter the observed effects of added heparin [47]. However,
no differences were observed between C751 isolates grown on
GC-agarose medium with highly purified agarose as a gelling
agent (see Methods), or those grown on HBHI (Figure S4).
In an attempt to analyse the relative preference for bacterial
binding directly to the Y-S of Vn or HBD through heparin,
experiments were performed using heparin and VA-21S as
inhibiting agents. Inhibition of aVn binding to bacteria was
observed at increasing heparin as well as VA-21S concentrations
(Figure 8A1), this may suggest a common site on Opc for binding
directly to Vn and to heparin.
On a closer examination of the effect of heparin when used at
low concentrations in ELISA, a biphasic effect was observed: an
initial decrease followed by a small rise in binding which was not
sustained as heparin concentration increased and eventually there
was an overall decrease in bacterial binding to aVn (Figure 8A2).
This biphasic effect of heparin suggested that in the presence of
low levels of heparin, two competing interactions with aVn may
occur. Some bacterial binding may continue to occur at the
tyrosine sulphated site; in addition, binding to HBD via the bound
heparin may also come into play. An interesting observation from
this study was that the presence of heparin did not produce more
binding to aVn than observed in its absence at any concentration.
This might suggest that while the presence of limited amount of
heparin in an ELISA may alter the site of bacterial binding on
aVn, this alternative binding is of a lower affinity than the binding
to sulphated region of Vn CR.
B306 as a modulator of direct and indirect binding. As
implied in the above studies, if Nm Opc contains a single or
overlapping binding site/s for both Y-S and heparin, then the
indirect Vn-binding might also be expected to be inhibited by the
anti-Opc mAb B306, which inhibits the direct binding (Figure 7E).
To assess the effect of B306 on heparin-mediated binding, first
bacteria were coated with B306 and then with heparin. These
bacteria adhered to aVn at the same level as those coated with
B306 alone. Similarly, in a reverse coating sequence, bacterial
adherence levels were dictated by the first coating of heparin (not
illustrated). These observations suggest that B306 also inhibits
heparin interactions with Opc.
Dual binding sites of Opc on activated vitronectin
To finally demonstrate the dual mechanisms of Vn targeting by
Opc, we raised and tested the following hypothesis, taking into
account that a single site of Opc may bind to the sulphated regions
of Vn and heparin. If Opc
+ Nm were precoated with heparin and
the excess removed, bacterial adhesion could only occur via the
heparin-binding domain/s of Vn as the Y-S-binding region of Opc
would be fully occupied with heparin. In the presence of excess
heparin, the HBD domain of Vn should also be saturated. This
should prevent all Opc interactions with Vn. However, it has to be
noted that an induced-fit mechanism of ligand-targeting might be
involved in binding of Opc to its ligands [19]; in this case, some
differences may exist in binding of Opc to the CR of Vn and to
heparin.
To test this hypothesis, aVn was overlaid with uncoated or
heparin-precoated bacteria in the absence or presence of excess
8E6 to block the Y-S site or excess heparin to block the HBD of
Vn. The direct binding of uncoated Opc
+ Nm was inhibited by the
addition of 8E6 as well as in the presence of excess heparin. Pre-
coating Opc
+ bacteria with heparin before measuring their
binding to activated Vn shows lower binding (by ,50%) than
uncoated bacteria (4
th bar, Figure 8B) suggesting a lower affinity of
binding through this route. In addition, unlike uncoated bacteria,
the presence of 8E6 does not affect the level of binding of heparin-
precoated bacteria (also represented by the 4
th bar, Figure 8B). As
the mAb 8E6 binds to the Y-S region, it may not be expected to
interfere with Nm binding at the distally located HBD domain in
the activated form of Vn. Excess heparin (with or without 8E6)
itself by binding to HBD, competes with heparin-coated Nm and
almost completely inhibited bacterial binding to Vn in accordance
with the above hypothesis. This is consistent with the binding of
coated and uncoated bacteria at distinct regions of Vn. In
addition, the direct binding to sulphotyrosine region of Vn has
already been established above (Figure 6). A proposed sequence of
events consistent with the data is illustrated in Figure 8C. Figure 9
summarises some of the Vn properties and illustrates the binding
sites for Opc
+ Nm on activated human vitronectin.
Discussion
For a number of human pathogens, extracellular matrix and
serum proteins serve as mediators of anchorage to host cell
surfaces, a process that often leads to cellular invasion
[1,2,4,48,49]. Fibronectin and vitronectin have been shown
repeatedly to serve as such molecular bridges. However, their
binding by microbes may itself occur indirectly via heparin, as Fn
and Vn are both heparin-binding proteins and many bacteria can
bind to heparin-like negatively charged polymers [46,50,51].
Only a limited number of studies have been carried out on Nm
Opc and its requirements for binding to Fn/Vn and subsequent
attachment to human cells. Some pertinent observations from
these studies are outlined below. It appears that Nm Opc and a
related but distinct class of neisserial adhesins, the Opa proteins,
may directly bind to Fn, Vn was not investigated in this study [52].
Eberhard et al. [52] also observed the direct binding of several
Opa
+ Opc
+ capsulate strains of Nm to the central cellular binding
domain of Fn. Further, they demonstrated similar binding of Nm
isolates to immobilised cFn and pFn but much reduced
interactions were observed when pFn was provided in solution.
As cFn and pFn have structural differences, their interactions with
bacteria may differ. In addition, immobilisation of pFn may also
lead to altered conformation of the molecules which may affect
observed binding levels.
On the other hand, other studies have illustrated a possible
requirement for sulphated bridging ligands for Nm Opc/Vn
interactions [46]. These studies used dextran sulphate as a
substitute for heparin which increased Opc binding to Vn
significantly over that observed in the absence of any bridging
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dextran sulphate; notably, dextran sulphate supported stronger
interactions with Fn and Vn than heparin [46].
To define the role of Opc, in our previous studies, defined
acapsulate isolates of Nm strain C751 and MC58 either expressing
or lacking the expression of Opc, direct Nm Opc-mediated
binding to Vn was shown, which resulted in increased adhesion
and invasion of HUVECs [1,2]. Our preliminary observations also
suggested that Opc may bind directly to purified Fn and its
binding to purified cFn was somewhat better than to the pFn
preparation employed [1]. More recent studies of Unkmeir et al.
(2002) that used Opa and pili-expressing capsulate phenotypes of
Nm, did not observe a role for Vn in mediating HBMEC adhesion
or invasion, rather an inhibition of basal cellular invasion was
Figure 8. Biphasic effect of heparin on bacterial interactions with human vitronectin. ELISA plates with immobilised acapsulate Opc
+ Nm
were blocked with BSA block (pre-filtered using heparin-sepharose and DEAE-sephacel) and then overlaid with heparin or VA-21S peptide at the
concentrations shown for 20 min prior to the addition of aVn (2.5 mg/ml). Vitronectin binding was assessed as described in Methods. In A1, the results
observed over the full range of concentrations are shown whereas in A2 data at a narrower range of heparin concentrations are depicted and VA-21S
data are included for comparison. The level of binding in the presence of the control peptide VA-21 when used at a concentration of 100 mg/ml is
shown by an asterisk in A1. Data shown are representative of two independent experiments performed using bacteria grown either on GC-agarose or
HBHI. Identical results were obtained in both cases. (B) ELISA plates with immobilised aVn were overlaid with uncoated or heparin-precoated bacteria
in the absence or presence of excess 8E6 or heparin (Hep
++) or both (Hep
++,8E6) during the incubation. Bacterial binding was assessed using
polyclonal anti-Nm antibody. In each case, percent binding to Vn relative to the highest value observed (i.e. uncoated bacteria in the absence of
inhibitors) are shown. (C) The sequence of events consistent with the data in B is represented in a schematic diagram. The horizontal lines represent
unfolded Vn molecule (Vn) with its N terminal ‘Y-S’ domain and C-terminally located heparin-binding domain (HBD). These regions may constitute
two separate binding sites for Nm on Vn (triangles: mAb 8E6, diamonds: heparin, open circles: uncoated Opc
+ Nm, filled circles: heparin-coated Opc
+
Nm). a: uncoated Nm bind directly to the Y-S region; b: the mAb 8E6 also binds to Y-S and blocks binding of Nm to the site; c: excess heparin present
in the medium coats bacteria and prevents binding to Y-S and in addition, it binds to the HBD and prevents hep-coated Nm binding to HBD; d: Nm
precoated with heparin cannot bind to Y-S but in the absence of excess heparin, can bind to HBD; in this case added mAb 8E6 does not affect the
level of Nm adhesion to Vn; e: excess free heparin added to the medium binds to HBD and blocks heparin-coated Nm binding to the site; again the
presence of mAb 8E6 binding at the CR of Vn has no effect.
doi:10.1371/journal.ppat.1000911.g008
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purified fibronectins, cFn appeared to be the more efficient form
in increasing bacterial invasion of HBMECs. Notably, there are
several differences in the choice of assay designs, cell lines and
bacterial phenotypes in the above investigations that may account
for the differences between the above observations. However, our
unpublished observations have shown that significant variations
can also occur in purified preparations of serum proteins from
distinct sources and may account for some of the reported
observations.
Sialylation and cellular interactions
It is well documented that in non-piliated Nm, the capsule and
sialylated LPS dampen the interactions of subcapsular adhesins
with their cell-expressed receptors [2,3,20]. However, in this
setting, additional expression of pili can overcome such dampen-
ing effects to bring the outer membrane adhesins and host cell
receptors in close apposition [6,7,8].
In order to assess the potential of Opc in capsulate as well as
acapsulate bacteria to bind to Fn or Vn conformers present in
human serum, in the current study, we employed two distinct
meningococcal strain isolates: those of Nm strain C751 with no
surface expression of capsule and those of strain MC58 with
capsule and intrinsically sialylated LPS. The latter also expressed
pili, Opa and Opc, representing a phenotype of relevance in in vivo
settings. The data show that the Nm Opc in such acapsulate and
capsulate bacteria can bind directly to human serum factors and
mediate endothelial cell adhesion and invasion. Our unpublished
studies also show that, in capsulate Nm, interactions of subcapsular
adhesins with the soluble serum effectors (e.g. Vn) are not
dependent on pilus expression; whereas their further interactions
with cellular receptors are facilitated by the presence of pili. Such a
role of pili in initiating the initial cellular engagement and leading
to facilitation/potentiation of the interactions of Nm with human
cells via integral outer membrane proteins has been established in
our previous studies on epithelial cells [6,7,8].
Figure 9. Vitronectin domain structure, conformational states and some physiological and bacterial ligand binding sites. (A) A
schematic presentation of linear vitronectin structure showing the positions of the cell-binding motif RGD, sulphated tyrosines (Y56S/Y59S) and the
high affinity heparin-binding domain (HBD), the three regions of particular importance in meningococcal interactions with host receptors. The N-
terminal domain contains a region homologous to somatomedin B, (SMB, residues 1–44). The central and the C-terminal domains contain regions
homologous to haemopexin (H1 and H2). An extended connecting region (CR) joins the N-terminal and the central domains and contains a stretch of
acidic residues (53–61) within which two sulphated tyrosines (Y-S) are located. This site is cryptic in the native vitronectin and comprises the mAb 8E6
binding epitope requiring the presence of sulphated residues [30]. The C-terminal domain residues 341–380 contain the main heparin-binding
domain (HBD) and are composed of several highly charged residues [26]. Arginine at positions 351/353 may bind directly to heparin [45]. Two other
sites implicated in heparin binding (but with low affinity) are shown as HB1 and HB2. Several pathogens bind to the central domain and via heparin
to HBD [46,64,65]. Only Nm has been shown in our current study to bind to the Y-S region in the vitronectin connecting region. Binding positions for
physiological ligands are shown (grey boxes). Information is partly based on [23,26,27] and references there in. (B) An illustration of the folded
conformation of the vitronectin molecule which may bring the acidic sulphated tyrosines and the basic HBD in close proximity [23]. (C) Under
physiological or in vitro denaturing conditions, Vn structure is relaxed exposing fully the HBD binding site and making available the mAb 8E6 epitope
in the CR, both with the capacity to bind to N. meningitidis Opc protein. The binding at the HBD may additionally be assisted by the multimerisation
of Vn, which increases the affinity of multimeric Vn for heparin [27]. The molecular model of Opc was kindly provided by Prof. Jeremy Derrick. The
Opc crystal structure has been described by Prince et al. [17]; this study also presents a model of the possible mechanism of interaction of the Opc
surface exposed loops with heparin-like proteoglycans.
doi:10.1371/journal.ppat.1000911.g009
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to Opc
+ Nm appear to be lower than of serum Vn and
consequently serum-dependent HBMEC adhesion and invasion
are significantly inhibited with 8E6, an aVn-specific mAb. In
addition, none of the purified Fn preparations supported adhesion
or invasion to the extent observed either with serum or certain
purified Vn preparations (i.e. aVn). These data confirm that Opc
can bind to human fibronectin but also suggest that Vn may be the
preferred target, as observed previously [1].
Opc
+ Nm interactions with vitronectin
Vitronectin occurs in two distinct conformations, a native
conformation with a cryptic heparin binding site and an unfolded,
active conformation with fully exposed binding sites for heparin/
heparan sulphate and the mAb 8E6 (see Figure 9 and associated
citations). In our earlier studies it had been noted that some, but
not all, preparations of Vn, supported efficient direct binding of
Opc-expressing Nm to Vn (unpublished observations). As Opc is a
heparin-binding protein and as it has been implied that Opc may
require sulphated bridging molecules to bind to Vn [46], detailed
investigations were undertaken to assess the direct as well as the
indirect binding requirements for Opc
+ Nm and the potential role
of Vn in supporting adhesion and invasion of endothelial cells of
human brain origin.
The role of vitronectin sulphation in Nm interactions
Opc may bind to Vn and Fn via a heparin bridge [20,46].
However, Nm Opc clearly also interacts with Vn directly, as this
occurs in the absence of added heparin. Notably, growth
conditions did not result in prior acquisition of sulphated
contaminants (as occurs with Neisseria gonorrhoeae [47]), that could
account for this observation, which could be specifically inhibited
by anti-Vn mAb 8E6 and by heparin. The mAb 8E6 has been
shown unequivocally to bind to the CR of Vn and require the
sulphation of the tyrosine residues Y56 and Y59 in the Vn
connecting region for efficient interactions with Vn [22,30,53].
However, 8E6 may inhibit bacterial binding via steric hindrance
as in the case of its inhibition of the urokinase-like plasminogen
activator receptor (uPAR) which binds to a region in the nearby
somatomedin B domain [30]. Further evidence for the involve-
ment of the 8E6 epitope as a major binding site for Nm Opc came
from the use of acid-desulphated Vn which no longer supports
either Opc
+ bacterial binding or mAb 8E6 binding presumably
due to the loss of acid-labile O-linked sulphated residues [30]. Acid
desulphation under mild conditions does not destroy the protein
antigenicity in general as shown in the current study (Figure 5).
Studies from other groups also report that acid desulphation does
not alter uPAR or PAI-1 binding to Vn [29]. It is also worth
noting that any phosphorylated amino acids present (such as
threonine 50 and 57) may not be affected by the acid-treatment
employed as O-linked phosphates are highly resistant to acid
hydrolysis [42,43] (as also demonstrated in Figure S1).
In addition, in our studies, sulphated peptide spanning the Vn
residues 48–68 (VA-21S) or the biotinylated VA-26S (spanning the
residues 43-68) significantly inhibited the binding of Opc
+ Nm to
aVn. The equivalent non-sulphated peptides (VA-21 or VA-26)
were only weakly inhibitory. Further, we also analysed the effect of
a synthetic peptide of Vn modified at Thr50 and Thr57 with
phosphate groups (VA-26P), as Vn can be modified at these
residues by the action of CK2 [39,40,41]. This peptide did not
inhibit bacterial binding to aVn even at high concentrations. The
VA-21/S peptides could not be immobilised effectively on to solid
surfaces; therefore the biotinylated VA-26/S/P peptides tethered
to extravidin immobilised on ELISA plates were used to assess the
direct binding of Nm. In this system also, Opc
+ Nm binding to
VA-26S but not to VA-26 or to VA-26P could be seen. The data
show clearly that Opc
+ Nm can target residues within the
connecting region of vitronectin and this is facilitated by the
sulphated tyrosines of the connecting region.
The minimal Vn features required for cellular invasion by
Opc-expressing meningococci
The RGD motif in the 26-mer peptides also enabled
immobilisation of the peptides on the endothelial integrins and
examination of the adhesion and invasion-supporting roles of the
26-mer VA-26/S/P peptides. From these studies it is clear that
sulphated tyrosines and the RGD motif as in VA-26S peptide are
required for mediating Opc-dependent cellular adhesion and
invasion of both capsulate and acapsulate meningococci.
Tyrosine sulphation of proteins
Tyrosine O-sulphation is a common post-translational modifi-
cation of secretory and membrane-bound proteins which takes
place in trans-Golgi network and is catalysed by membrane-
anchored tyrosylprotein sulphotransferases. The classes of proteins
that contain sulphotyrosines include G protein–coupled receptors,
adhesion molecules, coagulation factors, hormones and extracel-
lular matrix proteins [31,54]. In vitronectin, the residues Y56 and
Y59 have been unambiguously determined as the tyrosine
sulphation sites [29,30,31]. It has been proposed that the
sulphated tyrosine residues of Vn have a role in its conformational
stability as the highly acidic tyrosine sulphated region binds
intramolecularly to the highly basic heparin-binding region at the
C-terminal end of Vn thereby locking vitronectin in an inactive
conformation (as depicted in Figure 9) [29,31].
There is increasing evidence that sulphotyrosines partake in
protein-protein interactions in the extracellular space and the
modification has been shown in many cases to be required for
efficient ligand-receptor interactions. Its importance has been
reported particularly for chemokine receptor functions [55].
Interestingly, HIV enters macrophages and T cells via interacting
with sulphated residues of the chemokine receptor CCR5 [56].
However, to our knowledge, such an involvement of sulphated
tyrosines in bacterial targeting of host receptors and pathogenesis
has not been previously reported.
Opc binding to Vn via heparin
As sulphated residues are involved in mediating both the direct
binding to the CR and in indirect binding to HBD, it is very likely
that the same region of Opc is involved in these two interactions. If
a common site binds to the sulphates of these diverse receptors, it
may be envisaged that, at certain low heparin concentrations,
bacterial binding to the HBD could occur via a heparin bridge
and, a level of bacterial binding could also occur directly to the
sulphated tyrosines via Opc sites unoccupied by heparin. On the
other hand, in the presence of excess heparin, all Y-S binding sites
on Opc may be occupied and in addition, the HBD on Vn may
also be blocked by heparin. Thus, Opc-mediated interactions may
be totally inhibited. This was indeed the case (data in Figure 8). In
addition, in the absence of any free heparin, heparin precoated
bacteria (which can only bind to Vn via the HBD) bind less
effectively to Vn than uncoated bacteria suggesting that binding to
HBD via heparin is of a lower affinity than direct binding to the Y-
S site in the Vn connecting region.
As iterated above, in previous studies to demonstrate the
requirement for sulphated ligands in indirect Opc/Vn interactions
[46], low levels of Opc
+ Nm binding to Vn occurred in the
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sulphate relatively higher binding to Vn was observed. Notably, in
these studies, heparin was less efficient than dextran sulphate for
the indirect binding of Opa-expressing N. gonorrhoeae to Vn and Fn.
Thus, affinities of such different sulphated ligands for Opc (and
Opa) may vary considerably and in turn affect the efficacy of
vitronectin targeting. As our current studies have used heparin
solely, we can only draw conclusions about the relative affinities
for heparin-dependent and independent interactions of Opc
with Vn.
It is pertinent to note also that Opc
+ Nm binding to native Vn
did not change in the presence of added heparin (data not
illustrated), and the binding levels of Opc
+ and Opc
2 phenotypes
were similar to those shown in Figure 4 for direct Opc
+ Nm
interactions with native Vn. This suggests that the activated,
unfolded vitronectin is the only target for effective direct or
indirect binding of Nm.
Species specificity
Vitronectin is evolutionarily highly conserved [23]. Examina-
tion of the sequences within the CR of human, bovine and murine
vitronectins revealed that Y56 is conserved in all three proteins but
Y59 is not present in bovine Vn. However, we observed
experimentally that the mAb 8E6 binding requirements were
only present in human Vn. Nonetheless, Opc
+ Nm binding to both
bovine and murine vitronectins was found to be significantly
higher compared with Opc
2 Nm. As acid hydrolysis destroyed
these interactions, Y56S residue and other tyrosines located at Y59/
Y61 may significantly contribute to Nm binding to bovine and
murine vitronectins also. Tyrosine sulphate modification of
proteins is not uncommon among eukaryotic proteins and it has
been observed that sulphated tyrosines are often grouped together
in defined clusters and are frequently flanked by acidic residues
[54]. The environments in the bovine and murine vitronectins are
thus favourable for sulphation and for bacterial binding but
apparently not for 8E6 binding, which clearly has a more strict
epitope requirement; accordingly, the mAb has a very limited
number of targets especially in human serum [53]. We also
observed that, the anti-Opc mAb B306 against the Opc loop 2
inhibited Opc
+ Nm binding to all three vitronectins suggesting that
the adhesin binds to the three proteins using largely similar
mechanisms. Finally, VA-21S (with human Vn sequence) also
significantly inhibited Nm Opc interactions with the animal-
derived vitronectins, also suggesting similar mechanisms of binding
to the three vitronectins. Further site-directed mutagenesis of both
Opc and of various animal/human vitronectins are required to
finally confirm the observations.
In vivo implications
Vitronectin is one of the more abundant plasma proteins circulating
at ,200–400 mg/ml in humans and makes up 0.2–0.5% of total
plasma proteins [23,26]. Only a small proportion (,2%) has been
estimated to be in its activated state in plasma but after coagulation, in
serum this may increase to ,7% [33]. However, conformational
changes in the protein occur in vivo as it becomes activated by the
interactions of circulating ligands such as TAT and MAC complexes
which increase during pathogenic conditions. Among other functions,
Vn serves as scavenging receptor for the end products of the
haemostasis and complement systems and complexed Vn is rapidly
cleared from circulation [23,57]. Increased native Vn consumption
due to continuous activation of Vn during disseminated Nm infections
may indeed occur [28]. The availability in several such complexes for
the mAb 8E6 binding site [28,36] suggests that Nm Opc may also be
able to target any activated Vn sequestered into the complexes, which
is under investigation. The frequent conversion of native Vn to
activated Vn ensures a constant supply for bacterial binding which
could lead to increased cellular interactions at the brain and
vascular endothelialinterfacesandanincreasedpotential totraverse
the barriers as observed in vitro. This study has demonstrated that
capsulate meningococci can interact with HBMECs via Opc/Vn
bridge; the studies of Unkmeir et al. [4] have shown this to be the
case via Fn. Whether such interactions occur in vivo remains to be
shown. As murine Vn may support Opc binding, suitable animal
models could be used to assess this phenomenon. However, it is
noteworthy that the efficacy of subcapsular adhesins in mediating
cellular interactions of capsulate phenotypes may only be effectively
observed when the bacteria are also piliated (as discussed above).
Accordingly, with respect to pilus receptor expression, humanised
animal models may be required in order to assess the in vivo
significance of the reported findings. Finally, as reported for other
pathogens, in addition to increased cellular interactions, vitronectin
binding could also enable bacteria to become more serum resistant
(N. J. Griffiths and M. Virji, manuscript in preparation; [58]). Thus,
the targeting of activated vitronectin may impart to Opc-expressing
meningococci the properties of efficient tissue penetration and
resistance to host innate and adaptive immunity required for
effective dissemination.
Materials and Methods
Bacteria and growth conditions
N. meningitidis phenotypes with or without the expression of Opc
(Opc
+, Opc
2) were derived from the serogroup A strain C751 and
have been characterised and described previously [3,10]. These
isolates are acapsulate and do not express the other major adhesins
Opa or pili. Their outer membrane profiles by SDS-PAGE appear
identical other than in the expression of Opc protein. They express
pilin monomerswhichareincorporatedintheoutermembranesbut
these are not assembled into pili by EM and are not functionally
effective [3,7]. Their reactivity with a number of anti-LPS mAbs is
also identical, they possess lactoneotetraose in LPS which can be
onlyextrinsicallysialylated inserogroupA Nm.Asblood isolatesare
usually capsulate and express pili and the opacity adhesins Opa and
Opc, to investigate the role of Opc in adhesion and invasion of
endothelial cells bysuchcapsulate bacteria, Opc
+ and Opc
2 isolates
ofserogroupB MC58 strainwereusedwhich were otherwisereplete
with capsule, pili and Opa expression. These isolates express L3
LPS immunotype which can be intrinsically sialylated [6].
All meningococci were normally grown on brain-heart infusion
agar supplemented with heated horse blood (HBHI) [35]. This
medium contains some sialic acids from the blood supplement and
so the LPS of the serogroup A strain C751 can become
extrinsically sialylated. In some experiments where indicated, a
defined GC-agarose medium (utilising ultrapure agarose as the
gelling agent [59]) was used for the growth of this strain. In this
case, no serum supplement is present, thus there is no source of
sialic acid for incorporation into LPS. Notably, no qualitative or
significant quantitative differences in Vn targeting were observed
when using C751 isolates grown on these two media (Figure S4).
Cell lines
Human brain microvascular endothelial cell line (HBMEC) was
kindly provided by Dr K. S. Kim, John Hopkins University, USA
[60]. Cells were grown in RPMI-1640 medium supplemented with
15% (v/v) heat-inactivated foetal calf serum (FCS) (Cambrex),
2 mM glutamine, 1 mM sodium pyruvate, 100 U ml
21 penicillin-
streptomycin, 1% (v/v) MEM non-essential amino acids solution
and 1% MEM vitamins solution at 37uCi n5 %C O 2.
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Anti-Vn mAb clone 8E6 (Millipore) was used to detect and
block the interactions of activated Vn at 1–5 mg/ml and 10 mg/ml
respectively. The monoclonal anti-Vn antibody VIT-2 and
polyclonal anti-Fn antibodies were obtained from Sigma and
polyclonal anti-Vn antibody was from Millipore (AB19014). Anti
phosphothreonine (Sigma) (anti-Thr-P) was used at a range of
dilutions as indicated to detect phosphorylation of threonine
residues in the synthetic peptide VA-26P. Anti-Opc mAbs B306
and 154,D-11 were kindly provided by Prof. M. Achtman and Dr.
J. Kolberg respectively [61,62]. Where not stated, the antibodies
were used at predetermined optimum concentrations (usually,
1–10 mg/ml).
Purified proteins and synthetic peptides
Native Vn was purchased from Molecular Innovations. Fibro-
nectin and activated Vn from normal human serum (purified using
heparin-sepharose chromatography) were obtained from Sigma.
Synthetic peptides corresponding to the Vn residues 48–68 (VA-21)
and the corresponding sulphated peptide (VA-21S) were used in
competition experiments. As these could not be immobilised
efficiently to solid surfaces, biotinylated peptides were also used.
These peptides spanned the Vn residues 43–68 (VA-26) and at
positions 45–47 they containedtheRGD cell bindingsequence asin
Vn. The unmodified VA-21, VA-26 and the phosphorylated VA-
26P were obtained from GL Biochem (Shanghai, China). The
sulphated peptides VA-21S and VA-26S were synthesised by
Cambridge Research Biochemicals (Cambridge, UK).
Bacterial binding to serum proteins
Heat-treatment of NHS. Decomplemented serum was used
in the reported experiments to suppress any bactericidal effects.
However, although such heat treatment is known to convert native
vitronectin to an unfolded state, the decomplemented serum still
contained a substantial level of native Vn as assessed by heparin
sepharose fractionation in which aVn can be differentially
removed as nVn does not bind to heparin efficiently [23].




2 Nm with 10% decom-
plemented NHS. Bacteria were then harvested, washed three
times prior to the analysis for bound serum proteins. Bacterial
lysates were subjected to SDS-PAGE and western blotted, and the
presence of the proteins detected using anti-Vn or anti-Fn
antibodies.
For assessment of the preference for binding to activated Vn,
native Vn or Fn, their depletion from serum was analysed by
sequential adsorption of a serum sample with three freshly
prepared live bacterial suspensions. Incubations were carried out
for an hour and an aliquot of the serum sample was retained. The
rest of the sample was subjected to further adsorption with fresh
bacterial suspensions. The adsorbed serum aliquots were analysed
for the levels of total and activated Vn as well as Fn by immuno-
dot blot assays as described below.
Measurement of bacterial adhesion and invasion
Total cell association (adhesion) and invasion were measured by
viable count assays as described previously [35]. Briefly, for cell
association, bacterial suspensions were incubated with cell
monolayers at an MOI of 300:1 in medium 199 supplemented
as required with pre-determined optimum concentrations of serum
or purified proteins and peptides for an infection period of 3 h.
After this, target cells were lysed in a 1% saponin solution, diluted
and plated. Levels of bacterial invasion were determined by
gentamicin protection assays and verified by the use of
cytochalasin D [10,35]. Optimum concentrations of supplements
required to support adhesion and invasion were found to be 10%
for decomplemented NHS and 10 mg/ml of the purified serum
components used. To unfold Vn preparations, in some exper-
iments, samples of purified Vn preparations (human nVn, bovine
and mouse Vn samples) were treated by heating at 56uC for
30 min. The details of experiments to test the effects of Vn
peptides or antibodies on bacterial interactions with HBMECs are
described in the text.
Immunofluorescence assays
In some experiments, bacterial adhesion levels were visualised
by microscopy after fluorescent labelling of bound bacteria as
described previously [63]. Briefly, cell monolayers with adherent
bacteria were fixed with methanol and non-specific binding sites
blocked with 3% BSA in phosphate buffered saline containing
0.05% Tween-20 (PBST). Bacteria were detected by overlaying
with a rabbit polyclonal antiserum raised against Nm and
secondary antibodies conjugated to rhodamine.
Immuno-dot blot assays
Activated Vn, native Vn, or heat-treated nVn were dotted onto
nitrocellulose at a starting concentration of 375 ng/dot followed
by serial 2-fold dilutions, and non-specific binding sites blocked
with 3% BSA-PBST. Nitrocellulose strips were then overlaid with
anti-Vn antibodies and their binding was detected using alkaline
phosphatase (AP)-conjugated secondary antibodies. In some
experiments bacterial binding to immobilised Vn was assessed
using Opc
+ Nm (1610
10 bacteria/ml) which were allowed to bind
to immobilised Vn for 2 h. Bacterial binding was detected using
polyclonal antiserum against Nm and AP-conjugated secondary
antibodies. Relative levels of antibody binding were ascertained by
densitometry using Scion Image software (Scion Corporation,
Maryland USA).
Acid hydrolysis of vitronectin and peptides
Vitronectin samples and biotinylated peptides were treated with
1 M HCl to remove O-linked sulphate groups from the tyrosine
residues [30]. In addition, the effect of such acid treatment on
phosphorylated peptides was also monitored. Briefly, 2.5 mg of the
appropriate Vn stock or 5 mg of VA-26S/VA-26P biotinylated
peptides were incubated for up to 20 min at 80uC in 1 M HCl
before neutralising with 1 M Tris. The level of sulphation of the
human aVn (or sulphated peptides) was then determined by
immuno-dot blot using the mAb 8E6. Phosphorylation status of
VA-26P after acid treatment was monitored by the use of anti-
Thr-P antibody.
Enzyme linked immunosorbant assay
ELISA plates (96 well, Dynex) were incubated overnight with
purified Vn in PBS or in carbonate buffer pH 9.5. For direct
binding studies, Opc
+ Nm were added at 10
8 bacteria/well in
PBS. The role of heparin was investigated by pre-coating bacteria
with 50 mg/ml heparin (Sigma) for 30 min, followed by washing
to remove excess heparin prior to the addition to wells in the
presence or absence of an additional 50 mg/ml heparin, which
was present throughout the initial binding period. In all cases,
bacterial binding was detected by the addition of a rabbit
polyclonal antiserum raised against Nm followed by AP-
conjugated secondary antibody. All antibodies were incubated
for 1 h at room temperature in 1% BSA-PBS. Plates were
developed using SigmaFast p-Nitrophenyl phosphate substrate
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ELISA procedures for detecting the binding of Vn to immobi-
lized bacteria were also performed and the Vn binding detected
with polyclonal anti-Vn antibody and developed as above. Where
heated native Vn was used for overlay, samples were heated for
30 min at 56uC prior to addition to wells. For biotinylated
peptide ELISA, plates (as above) were incubated overnight with
10 mg/ml extravidin (Sigma). Biotinylated peptides were then
immobilized at concentrations described in the text, for 1 h.
Unbound peptides were removed by washing. In some tests,
peptide loading was assessed using the mAb 8E6 or anti-Thr-P
antibody as described above or using competitive ELISA as
described in Figure S2. Peptide-containing ELISA plates were
used to assess the direct bacterial binding at a variety of peptide
and bacterial concentrations. Bound bacteria were detected by
appropriate antibodies as above.
Statistical considerations and data presentation
In general, one typical of several independent experiments is
shown. At least triplicate determinations were included within
each experiment and mean values with standard errors have been
shown.
Supporting Information
Figure S1 Acid hydrolysis of Vn peptides removes sulphated
residues specifically. To test the effect of acid treatment on the
stability of sulphate modification vs. phosphate modifications of
the biotinylated vitronectin peptides, acid treated and untreated
peptides were immobilised (5 mg/ml each) on ELISA plates pre-
loaded with 10 mg/ml extravidin and the levels of sulphation and
phosphorylation assessed using antibodies 8E6 and anti-Thr-P
respectively. The data demonstrate the specific removal of
sulphates with the treatment, as 8E6 binding is diminished but
not anti-Thr-P binding.
Found at: doi:10.1371/journal.ppat.1000911.s001 (0.14 MB TIF)
Figure S2 Immobilisation of biotinylated peptides on extravidin
ELISA plates. (A) Optimum concentration of extravidin for
coating ELISA plates was pre-determined and was found to be
10 mg/ml. The levels of biotinylated peptides immobilised on
extravidin plates were assessed using different concentrations of
VA-26S and VA-26P biotinylated peptides. The concentration
dependent binding of VA-26S is illustrated. In addition, the
maximum binding of VA-26P is shown which was achieved at
,5 mg/ml peptide. (B) As no antibodies to detect unmodified
biotinylated VA-26 were available, to assess its binding to
extravidin plates, competition ELISA was performed using
biotinylated peptides as follows: VA26 alone, VA-26S alone or
VA-26 followed by VA-26S. Binding of the sulphated peptide was
detected using the mAb 8E6. The data show the binding of the
sulphated peptide is inhibited by prior coating the plates with the
unmodified peptide, which appears to bind as efficiently as the
VA-26S peptide to extravidin coated plates.
Found at: doi:10.1371/journal.ppat.1000911.s002 (0.18 MB TIF)
Figure S3 Opc region/s involved in the direct and indirect
targeting of human vitronectin. Two mAbs against Opc were used
to assess their inhibitory effects at different concentrations using
activated Vn (aVn). A dose-dependent inhibition of binding of
aVn to immobilised bacteria in the presence of the anti-Opc mAb
B306 against loop 2 was observed but the mAb 154,D-11 against
loops 4/5 had no significant effect even at 50 mg/ml suggesting
that the Opc binding site for Vn resides close to the antibody B306
binding site on the adhesin, or that B306 restricts the induced fit
interaction of Opc with its ligand. Further studies were performed
on bovine and murine vitronectins using 30 mg/ml of the
antibodies and the data are shown in Figure 7E.
Found at: doi:10.1371/journal.ppat.1000911.s003 (0.11 MB TIF)
Figure S4 The effect of different bacterial culture conditions on
C751 Opc
+ Nm interactions with vitronectin. Untreated bacteria
cultured on HBHI or GC-agarose media were immobilised on to
ELISA plates (10
8 per well). The plates were blocked with heparin-
sepharose and DEAE-sephacel-filtered BSA block, and the
bacteria were then overlaid with 50 mg/ml of the peptides VA-
21S and VA-21 or heparin (used at 33 mg/ml) for 20 min,
followed by aVn (added at 2.5 mg/ml) for 1 h. Vn binding was
assessed using polyclonal anti-Vn antibody and alkaline phospha-
tase-conjugated anti-rabbit secondary antibody. In each case,
similar results were obtained whether bacteria were grown on
HBHI or on GC-agarose indicating that no interfering substances
were acquired by C751 isolates during growth on HBHI used in
the majority of the experiments.
Found at: doi:10.1371/journal.ppat.1000911.s004 (0.12 MB TIF)
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